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ABSTRACT  
Objectives: No long-term data have been published on the durability of response following 
pegylated interferon (PegIFN) treatment in children with chronic hepatitis C (CHC). This 
prospective, multi-center, long-term follow-up (LTFU) study aimed to assess long-term 
durability of sustained virological response (SVR), long-term safety and tolerability, and the 
association between IL28B genotype and treatment response, in children previously treated with 
PegIFN alfa-2a ± ribavirin (RBV) in the PEDS-C trial.  
Methods: Ninety-three patients were assessed for enrollment and 38 enrolled in the study. 
Patients attended two study visits: 5 (mean 5.6; range 4.1 - 6.6) and 6 (6.6; 5.1 – 7.7) years after 
treatment cessation. Standardized medical history, physical examination and laboratory testing 
were done at these visits. Reminder telephone calls were conducted at 4 and 8 months after the 
initial visit.  
Results: The LTFU cohort was representative of the original PEDS-C cohort as both baseline 
and treatment characteristics were comparable. Of the 38 participants, 21 achieved SVR 
(responders) during the PEDS-C trial and 17 had not (non-responders). All 21 responders 
maintained undetectable HCV RNA during the LTFU (4.4 - 7.0 years after achieving SVR) in 
contrast to the non-responders who demonstrated persistent viremia. IL28B CC genotype was 
associated with SVR (67%, vs. 30% in non-CC, p=0.028).  
Conclusion: Long-term durability of SVR is excellent following PegIFN alfa-2a treatment in 
children with CHC; SVR is higher in those with IL28B CC vs non-CC. 
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What is known: 
o There are ~5 million children in the world with chronic hepatitis C (CHC)  
viremia 
o Current FDA-approved therapy for children with CHC is pegylated interferon 
with  ribavirin 
o Durability of viral response in children treated with non-pegylated interferon and 
ribavirin is ~98% at 5 years of follow up 
 What is new: 
o Durability of viral response in children with HCV treated with pegylated 
interferon and ribavirin is ~100% at 4 – 7 years of follow up 
o Viral response in children treated with pegylated interferon and ribavirin is higher 
in children with IL28B CC vs. those with non-CC 
 
Abbreviations: 
CHC   chronic hepatitis C 
HCV  hepatitis C virus 
LTFU  long-term follow up 
LLOD  lower limit of detection 
CI  confidence interval 
PegIFN pegylated interferon  
RBV   ribavirin 
SAE  serious adverse events 
SNP  single nucleotide polymorphism 
SVR   sustained virological response 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
INTRODUCTION 
 
HCV infection is a significant global health burden, with an estimated prevalence of 
approximately 115 million people globally (1.6% of the world’s population) [1]. Eleven million 
of these individuals are below 15 years of age, of whom 5 million are viremic [1]. Children in 
China, Pakistan, Nigeria, Egypt, India and Russia account for more than 50% of the total 
pediatric infections [1]. Pediatric HCV infection prevalence varies significantly by region, 
ranging from 0.05-0.36% in the United States and Europe to 1.8-5.8% in some developing 
countries [2]. A similar trend is observed in the ratio of the prevalence of HCV in children 
compared to adults, which varies from approximately 1:25 in high-income countries to 1:4 in 
middle-income countries, and as high as 1:2 in low-income countries [1]. While vertical (mother-
to-infant) transmission is the major route of pediatric infection in developed countries, horizontal 
transmission (e.g. contaminated needles or blood transfusion products) is the major route in 
developing countries [2]. 
The PEDS-C study enrolled 114 children with chronic hepatitis C (CHC) into a clinical trial of 
pegylated interferon (PegIFN) alfa-2a (Pegasys ®) plus ribavirin (RBV, Copegus®) or placebo 
from December 2004 to May 2006 and the last patient completed the two-year follow-up in 
February 2010 [3]. The sustained virological response (SVR) rate was 53% (n=29/55) in children 
treated with combination therapy and 20% (n=12/59) in those treated with PegIFN alfa-2a plus 
placebo (p<0.001). SVR was maintained in 100% of children that were followed up for 2 years 
after cessation of therapy. In addition, 28/59 patients treated with PegIFN alfa-2a plus placebo 
were HCV RNA positive at Week 24, deemed non-responders and received additional ‘open-
label’ compassionate use PegIFN alfa-2a + RBV treatment for a further 48 weeks duration. 
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Eleven of these 28 patients (39%) ultimately achieved SVR, which was maintained in all patients 
2 years after completing treatment. 
Longer-term durability of response in children treated with PegIFN with or without RBV has not 
been reported to date. In adults, durability of SVR 5 years after completing PegIFN treatment has 
been observed to be >99% [4] and cirrhosis appears to be a risk factor for long-term relapse [5]. 
The only published report of long-term follow-up in children is following non-pegylated 
interferon treatment thrice weekly with RBV, where the Kaplan–Meier estimate for sustained 
response at 5 years was 98% (95% CI, 95-100%) [6].  
In adults with genotype 1 infection, several independent genome-wide association studies 
(GWASs) reported single nucleotide polymorphisms (SNP’s) near the IL28B (IFN-k) locus to be 
predictive of treatment response [7, 8].  Although recently a few pediatric studies have explored 
the effect of IL28B polymorphism on SVR in children, its role as a predictor of durability of 
response to treatment is still undetermined [9]. 
The purpose of this study was to perform a long-term follow-up (LTFU), up to 7 years after 
cessation of therapy, of a group of children previously treated with PegIFN alfa-2a ± RBV in the 
PEDS-C study, and assess the long-term durability of SVR, long-term safety and tolerability, and 
the association between IL28B polymorphism and treatment response. 
 
METHODOLOGY 
Study Population 
Patients were eligible for inclusion if they completed treatment with PegIFN alfa-2a ± RBV in 
the PEDS-C study. Patients were excluded if they received PegIFN alfa-2a ± RBV after the 
initial study period, received other treatment that the investigator judged could affect growth 
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(e.g. growth hormone therapy), or experienced serious illnesses unrelated to PegIFN treatment 
requiring >72 hours hospitalization that may have a negative impact on growth.  
Study Procedures 
The Institutional Review Board at each site and the Clinical Trials and Survey Corporation 
approved the study protocol. Informed consent was obtained from all patients, who were 
subsequently seen at study entry, contacted by telephone 4 and 8 months later, and seen again 1 
year after study entry. Clinical and laboratory information collected included: HCV RNA 
(TaqMan-2.0-EDTA-C Assay, LLOD 10 IU/ml), clinical chemistries and thyroid function tests, 
IL28B polymorphisms (SNPs at rs12979860, comparing genotype CC vs. CT/TT) [10], and 
health-related quality of life data. 
Statistical Analyses  
Descriptive statistics were used for all analyses with exploratory analyses performed as 
appropriate. All statistical tests were two-sided and used the conventional p<0.05 level of 
significance, with χ2 and independent t-test being used as appropriate. RNA values were log-
transformed to improve interpretability. All analyses were performed using SAS software 
version 9.2. 
RESULTS 
Subject Characteristics  
All 93 patients who had completed the 2-year follow up in the original PEDS-C study, from 8 
participating sites, were considered for enrollment. Thirty-eight were available and willing to 
participate in the LTFU study. Of the 55 others: 26 were not contactable, 8 had moved from the 
area, 7 received PegIFN/RBV re-treatment and 14 either refused consent or could not participate 
for other reasons. The patient disposition in the original PEDS-C study and this LTFU study is 
shown in Figure 1.  
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The LTFU cohort was found to be representative of the original PEDS-C cohort, both in terms of 
baseline characteristics (e.g. HCV genotypes) and treatment received (see Table). Twenty-one 
(55%) subjects had received PegIFN alfa-2a + RBV whilst 17 (45%) received PegIFN alfa-2a + 
placebo treatment. Ten of the 17 subjects treated with PegIFN alfa-2a + placebo, received 
additional PegIFN alfa-2a + RBV treatment for 24-48 weeks duration, after study week 24 via 
the ‘compassionate use’ treatment arm.  
Durability of SVR 
HCV RNA levels remained undetectable in 100% of responders but remained high in all non-
responders during LTFU. Mean ALT levels were significantly lower in responders compared to 
non-responders at all follow-up time points. For example at LTFU visit 1, mean ALT levels in 
responders were normal at 23 U/L [95%CI 19-27] while  they were elevated in non-responders at 
53 U/L [95%CI 32-75] (p<0.05).  
 
IL28B and SVR 
IL28B CC genotype was associated with higher rate of SVR, compared to CT/TT genotype (67% 
vs. 30% respectively, p = 0.028) (Figure 2). 
Safety Analyses  
There were no patient deaths and only 1 serious adverse event (hospitalization for depression) 
was reported. This SAE occurred 6.5 years post-treatment and was deemed unrelated to study 
treatment. There were no clinically significant changes in any laboratory or vital sign parameters 
with the exception of the HCV RNA and ALT values discussed above.  
Long-term growth outcomes have been previously reported [11], and overall no long-term 
effects on height were observed. The results of health-related quality of life questionnaires will 
be reported separately. 
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DISCUSSION 
The major finding of this study is that SVR following PegIFN alfa-2a ± RBV therapy in children 
with CHC is durable in 100% of patients for 4.4 to 7.7 years after treatment cessation. IL28B CC 
genotype was also observed to be associated with a greater chance of an SVR (p=0.028), which 
is consistent with data from adult and recent pediatric studies with CHC. Furthermore, PegIFN 
alfa-2a also shows an excellent long-term safety profile in treatment of children with HCV, 
including absence of long-term effects on growth [11]. 
The significance of the above finding is that PegIFN alfa-2a is currently widely available to the 
considerable global population of children and adolescents with HCV. Indeed, it has been 
estimated that approximately 50,000 HCV-infected infants are born every year [12], a fact which 
is especially sobering given that at present there is no known way to prevent maternal-fetal 
transmission.  
Although direct acting anti-viral agents currently hold great promise for highly effective 
interferon-free treatment regimens [13], none have yet been approved for use in children and 
there could be challenges to widespread availability to children, particularly in low-income 
countries where the prevalence and burden of HCV infection is greatest. 
The main limitation of this study is the relatively small number of patients that participated in the 
long-term follow-up. This is not surprising given that the average age of enrollees in the original 
PEDS-C study was 11 years and the long-term follow-up lasted up to 7.7 years after cessation of 
therapy. This meant that many patients had moved away from home for higher education or 
employment and were simply not available for participation in the LTFU study. However, the 
fact that the baseline and treatment characteristics of the LTFU cohort did not differ from the 
PEDS-C cohort indicates that the smaller LTFU cohort is representative of the original larger 
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cohort. Given that the LTFU cohort is representative of the larger cohort, it is unlikely that the 
100% long-term durability rates observed in the LTFU cohort would significantly differ if the 
entire PEDS-C cohort participated in the LTFU. 
Overall, the PEDS-C LTFU data indicate that children who achieve SVR during treatment with 
PegIFN alfa-2a, with or without RBV, have a very high likelihood of long-term maintenance of 
that response. Given the ~5 million HCV-infected children in the world, the current lack of 
approved direct-acting antiviral interferon-free regimes in the pediatric population, as well as the 
potential limited access to interferon-free regimens in the developing countries where HCV 
prevalence is highest, it is reassuring to confirm that SVR achieved in children with CHC with 
the current standard of care will be maintained for many years. 
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Table 1 Characteristics of PEDS‐C and LTFU Cohorts 
 
  PEDS‐C 
n=114 
LTFU 
n=38 
Demography, n (%)     
Male gender  63 (55)  23 (61) 
Non‐Caucasian race  23 (20)  7 (18) 
Age (years), mean ± SD  10.7 ± 3.4  9.7 ± 3.1 
5‐11 / 12‐17 yrs.  60 (53) / 54 (47)  25 (66) / 13 (34) 
BMI (kg/m2), mean ± SD  20.5 ± 4.9  20.1 ± 5.5 
Baseline Characteristics, n (%)     
HCV Genotype 1 / 2 / 3 / 6 
 
92 (81) / 7 (6) / 
13 (11) / 2 (2) 
31 (81) / 1 (3) / 
5 (13) / 1 (3) 
Perinatal infection route  85 (75)  29 (76) 
HCV RNA (Log IU/ML), mean ± SD  6.24 ± 0.83  6.12 ± 0.92 
ALT (U/L), mean ± SD  54 ± 36  51 ± 29 
Absent/minimal fibrosis (Ishak 0‐2)  104/110 (95)  35/36 (95) 
Treatment Characteristics, n (%)     
PegIFN alfa‐2a + RBV  55 (48)  21 (55) 
SVR  27/55 (49)  11/21 (52) 
PegIFN alfa‐2a + Placebo  59 (52)  17 (45) 
SVR  12/59 (20)  6/17 (35) 
Compassionate Use ‡  28/59 (47)  10/17 (59) 
SVR  11/28 (39)  5/10 (50) 
Treatment duration, 24 / 48 / 76 wks  26 (23) / 76 (67) 
/ 12 (10) 
5 (13) / 28 (74) 
/ 5 (13) 
‡ PegIFN monotherapy non-responders were eligible for additional compassionate use combination therapy treatment 
